MX375417B - Uso de ácido (r)-2-[3-[[n-(benzoxazol-2-il)-n-3-(4-metoxifenoxi)propil]aminometil]fenoxi]butírico o una sal, o solvato del mismo para el tratamiento de la esteatosis hepática no alcohólica, supresión de la deposición de grasa en el hígado, y en la reducción de células de kupffer en el hígado. - Google Patents
Uso de ácido (r)-2-[3-[[n-(benzoxazol-2-il)-n-3-(4-metoxifenoxi)propil]aminometil]fenoxi]butírico o una sal, o solvato del mismo para el tratamiento de la esteatosis hepática no alcohólica, supresión de la deposición de grasa en el hígado, y en la reducción de células de kupffer en el hígado.Info
- Publication number
- MX375417B MX375417B MX2016000307A MX2016000307A MX375417B MX 375417 B MX375417 B MX 375417B MX 2016000307 A MX2016000307 A MX 2016000307A MX 2016000307 A MX2016000307 A MX 2016000307A MX 375417 B MX375417 B MX 375417B
- Authority
- MX
- Mexico
- Prior art keywords
- treatment
- liver disease
- fatty liver
- drug
- nonalcoholic fatty
- Prior art date
Links
- 239000003814 drug Substances 0.000 title abstract 3
- 208000008338 non-alcoholic fatty liver disease Diseases 0.000 title abstract 3
- 229940079593 drug Drugs 0.000 title 1
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Chemical compound CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 abstract 2
- 230000002265 prevention Effects 0.000 abstract 2
- 239000004480 active ingredient Substances 0.000 abstract 1
- 125000004202 aminomethyl group Chemical group [H]N([H])C([H])([H])* 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 125000000951 phenoxy group Chemical group [H]C1=C([H])C([H])=C(O*)C([H])=C1[H] 0.000 abstract 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 239000012453 solvate Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/423—Oxazoles condensed with carbocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
La presente invención proporciona un compuesto útil en la prevención y en el tratamiento de la esteatosis hepática no alcohólica. La invención se refiere a un fármaco para la prevención y/o el tratamiento de la esteatosis hepática no alcohólica, el fármaco tiene como ingrediente activo ácido (R)-2-[3-[[N-(benzoxazol-2-il)-N-3-(4-metoxifenoxi)propil]aminometil]fenoxi]butírico, una sal del mismo, o un solvato de estos.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2013144643 | 2013-07-10 | ||
| PCT/JP2014/068253 WO2015005365A1 (ja) | 2013-07-10 | 2014-07-09 | 非アルコール性脂肪性肝疾患治療剤 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2016000307A MX2016000307A (es) | 2016-05-05 |
| MX375417B true MX375417B (es) | 2025-03-06 |
Family
ID=52280043
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2016000307A MX375417B (es) | 2013-07-10 | 2014-07-09 | Uso de ácido (r)-2-[3-[[n-(benzoxazol-2-il)-n-3-(4-metoxifenoxi)propil]aminometil]fenoxi]butírico o una sal, o solvato del mismo para el tratamiento de la esteatosis hepática no alcohólica, supresión de la deposición de grasa en el hígado, y en la reducción de células de kupffer en el hígado. |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US20160136138A1 (es) |
| EP (1) | EP3020401B1 (es) |
| JP (1) | JP6391572B2 (es) |
| KR (1) | KR102034703B1 (es) |
| CN (2) | CN114848637A (es) |
| AU (1) | AU2014288272B2 (es) |
| CA (1) | CA2917489C (es) |
| EA (1) | EA201690199A1 (es) |
| ES (1) | ES2772754T3 (es) |
| HK (1) | HK1218078A1 (es) |
| IL (1) | IL243481B (es) |
| MX (1) | MX375417B (es) |
| NZ (1) | NZ716421A (es) |
| PL (1) | PL3020401T3 (es) |
| PT (1) | PT3020401T (es) |
| TW (1) | TWI696462B (es) |
| WO (1) | WO2015005365A1 (es) |
Families Citing this family (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI691331B (zh) * | 2014-09-26 | 2020-04-21 | 日商興和股份有限公司 | 脂質異常症治療劑 |
| MX386778B (es) | 2015-03-09 | 2025-03-19 | Intekrin Therapeutics Inc | Métodos para el tratamiento de enfermedad de hígado graso no alcohólico y/o lipodistrofia. |
| SG10202012080UA (en) * | 2016-06-03 | 2021-01-28 | Chemocentryx Inc | Method of treating liver fibrosis |
| JP2019059673A (ja) * | 2016-08-25 | 2019-04-18 | 興和株式会社 | Ｐｂｃの治療剤 |
| JP7202892B2 (ja) * | 2017-01-11 | 2023-01-12 | 興和株式会社 | 非アルコール性脂肪性肝疾患の予防及び治療薬 |
| EP4424364B1 (en) | 2017-03-28 | 2026-01-21 | Gilead Sciences, Inc. | Combinations for use in the treatment of cirrhosis and liver fibrosis |
| WO2018187350A1 (en) | 2017-04-03 | 2018-10-11 | Coherus Biosciences Inc. | PPARγ AGONIST FOR TREATMENT OF PROGRESSIVE SUPRANUCLEAR PALSY |
| WO2019004453A1 (ja) | 2017-06-30 | 2019-01-03 | 興和株式会社 | 医薬品 |
| US20200129483A1 (en) * | 2017-06-30 | 2020-04-30 | Kowa Company, Ltd. | Pharmaceutical composition |
| WO2019004451A1 (ja) * | 2017-06-30 | 2019-01-03 | 興和株式会社 | 医薬組成物 |
| US20200121648A1 (en) * | 2017-06-30 | 2020-04-23 | Kowa Company, Ltd. | Pharmaceutical composition |
| WO2019004449A1 (ja) * | 2017-06-30 | 2019-01-03 | 興和株式会社 | 医薬組成物 |
| WO2019004447A1 (ja) * | 2017-06-30 | 2019-01-03 | 興和株式会社 | 医薬組成物 |
| JP6959049B2 (ja) * | 2017-06-30 | 2021-11-02 | 興和株式会社 | 新規低アルブミン血症改善薬 |
| KR102512518B1 (ko) | 2017-06-30 | 2023-03-21 | 교와 가부시키가이샤 | 페마피브레이트를 함유하는 의약 |
| CN110831592A (zh) * | 2017-06-30 | 2020-02-21 | 兴和株式会社 | 医药 |
| WO2019004452A1 (ja) * | 2017-06-30 | 2019-01-03 | 興和株式会社 | 医薬組成物 |
| CA3077273A1 (en) | 2017-10-06 | 2019-04-11 | Gilead Sciences, Inc. | Combination therapy comprising an acc inhibitor |
| JP7071538B2 (ja) | 2018-12-27 | 2022-05-19 | 興和株式会社 | 医薬組成物 |
| JP7058762B2 (ja) | 2018-12-27 | 2022-04-22 | 興和株式会社 | 医薬品 |
| JP2020105174A (ja) * | 2018-12-27 | 2020-07-09 | 興和株式会社 | 医薬組成物 |
| AU2022264289A1 (en) * | 2021-04-28 | 2023-11-02 | Kowa Company, Ltd. | Blood carnitine-increasing agent |
| MX2023013886A (es) | 2021-05-27 | 2024-04-19 | Kowa Co | Pemafibrato y/o tofogliflozin para uso en el tratamiento de enfermedad del higado. |
| JPWO2024010030A1 (es) * | 2022-07-06 | 2024-01-11 | ||
| CN119546300A (zh) * | 2022-07-15 | 2025-02-28 | 兴和株式会社 | 血中ldl胆固醇降低剂 |
| KR20240157567A (ko) | 2023-04-25 | 2024-11-01 | 부산대학교 산학협력단 | 지방간질환 치료 또는 예방 목적의 FXR/PPAR alpha 이중 작용 활성을 가지는 벤즈옥사졸 유도체 화합물 |
| WO2024225738A1 (ko) * | 2023-04-25 | 2024-10-31 | 부산대학교 산학협력단 | 지방간질환 치료 또는 예방 목적의 fxr/ppar alpha 이중 작용 활성을 가지는 벤즈옥사졸 유도체 화합물 |
| KR20250160539A (ko) | 2024-05-07 | 2025-11-14 | 계명대학교 산학협력단 | 지방간 질환 예방 또는 치료용 약학 조성물 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2004270538C1 (en) * | 2003-09-03 | 2010-01-14 | Kowa Co., Ltd | PPAR-activating compound and pharmaceutical composition containing same |
| ZA200601272B (en) * | 2003-09-03 | 2007-04-25 | Kowa Co | PPAR-activating compound and pharmaceutical composition containing same |
| US20080194575A1 (en) * | 2006-10-04 | 2008-08-14 | Naiara Beraza | Treatment for non-alcoholic-steatohepatitis |
| EP2484361B1 (en) * | 2009-09-28 | 2015-11-11 | Kowa Company, Ltd. | Agent for reducing visceral fat weight |
| US20130072459A1 (en) * | 2010-03-24 | 2013-03-21 | Gook-Jun An | Pharmaceutical composition for the prevention or the treatment of non-alcoholic fatty liver disease and the method for prevention or treatment of non-alcoholic fatty liver disease using the same |
| CN102892760B (zh) * | 2010-05-19 | 2014-05-07 | 兴和株式会社 | 非醇性脂肪性肝炎的预防和/或治疗剂 |
| US9023791B2 (en) * | 2010-11-19 | 2015-05-05 | Novartis Ag | Fibroblast growth factor 21 mutations |
-
2014
- 2014-07-07 TW TW103123292A patent/TWI696462B/zh active
- 2014-07-09 HK HK16106189.0A patent/HK1218078A1/zh unknown
- 2014-07-09 CN CN202210484918.2A patent/CN114848637A/zh active Pending
- 2014-07-09 MX MX2016000307A patent/MX375417B/es active IP Right Grant
- 2014-07-09 EA EA201690199A patent/EA201690199A1/ru unknown
- 2014-07-09 JP JP2015526365A patent/JP6391572B2/ja active Active
- 2014-07-09 CA CA2917489A patent/CA2917489C/en active Active
- 2014-07-09 US US14/903,114 patent/US20160136138A1/en active Pending
- 2014-07-09 AU AU2014288272A patent/AU2014288272B2/en active Active
- 2014-07-09 CN CN201480033804.XA patent/CN105307652A/zh active Pending
- 2014-07-09 ES ES14822133T patent/ES2772754T3/es active Active
- 2014-07-09 WO PCT/JP2014/068253 patent/WO2015005365A1/ja not_active Ceased
- 2014-07-09 KR KR1020157035313A patent/KR102034703B1/ko active Active
- 2014-07-09 EP EP14822133.6A patent/EP3020401B1/en active Active
- 2014-07-09 PL PL14822133T patent/PL3020401T3/pl unknown
- 2014-07-09 PT PT148221336T patent/PT3020401T/pt unknown
- 2014-07-09 NZ NZ716421A patent/NZ716421A/en unknown
-
2016
- 2016-01-04 IL IL243481A patent/IL243481B/en active IP Right Grant
Also Published As
| Publication number | Publication date |
|---|---|
| CA2917489A1 (en) | 2015-01-15 |
| KR102034703B1 (ko) | 2019-10-21 |
| HK1218078A1 (zh) | 2017-02-03 |
| US20160136138A1 (en) | 2016-05-19 |
| CN105307652A (zh) | 2016-02-03 |
| AU2014288272A1 (en) | 2016-01-21 |
| ES2772754T3 (es) | 2020-07-08 |
| EP3020401B1 (en) | 2019-11-13 |
| CN114848637A (zh) | 2022-08-05 |
| WO2015005365A1 (ja) | 2015-01-15 |
| PL3020401T3 (pl) | 2020-05-18 |
| IL243481A0 (en) | 2016-02-29 |
| AU2014288272B2 (en) | 2019-09-19 |
| EP3020401A1 (en) | 2016-05-18 |
| EA201690199A1 (ru) | 2018-01-31 |
| KR20160030479A (ko) | 2016-03-18 |
| PT3020401T (pt) | 2020-02-21 |
| IL243481B (en) | 2020-01-30 |
| EP3020401A4 (en) | 2017-02-15 |
| JPWO2015005365A1 (ja) | 2017-03-02 |
| TW201536283A (zh) | 2015-10-01 |
| TWI696462B (zh) | 2020-06-21 |
| MX2016000307A (es) | 2016-05-05 |
| CA2917489C (en) | 2021-05-04 |
| NZ716421A (en) | 2020-02-28 |
| JP6391572B2 (ja) | 2018-09-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX375417B (es) | Uso de ácido (r)-2-[3-[[n-(benzoxazol-2-il)-n-3-(4-metoxifenoxi)propil]aminometil]fenoxi]butírico o una sal, o solvato del mismo para el tratamiento de la esteatosis hepática no alcohólica, supresión de la deposición de grasa en el hígado, y en la reducción de células de kupffer en el hígado. | |
| CO6821938A2 (es) | Un compuesto de guanidina o una sal del mismo para el tratamiento de enfermedades relacionadas con vap -1 | |
| EA201691803A1 (ru) | Ингибиторы калликреина плазмы человека | |
| BR112015022197A8 (pt) | uso de um composto para fabricação de um medicamento ou composição farmacêutica para o tratamento de cataplexia | |
| MX380711B (es) | Composiciones veterinarias orales parasiticidas que comprenden agentes activos de accion sistemica, metodos y usos de las mismas. | |
| UA117103C2 (uk) | Сполука, яка має активність агоніста глюкагону | |
| IL231358A (en) | Topical veterinary compositions comprising an isoxazoline active agent for treating or preventing parasitic infection or infestation | |
| PE20140255A1 (es) | Tableta dispersable en forma oral | |
| ECSP14013329A (es) | Compuestos de arylcarbonil-4-oxy-piperidina utilizados para el tratamiento de enfermedades neurodegenerativas | |
| AR081681A1 (es) | METODOS Y COMPOSICIONES PARA LA ADMINISTRACION INTRATECAL DE b-GALACTOCEREBROSIDASA | |
| EA202090098A1 (ru) | Фармацевтические композиции терапевтически активных соединений | |
| CU20130126A7 (es) | Inhibidores sustituidos de acetil-coa carboxilasa | |
| BR112015027055A8 (pt) | bi-heteroarilas, usos das mesmas, e composição farmacêutica | |
| CR20140052A (es) | Un derivado novedoso de 1,2,3,4-tetrahidroquinolina útil para el tratamiento de diabetes | |
| DOP2016000253A (es) | Nuevos compuestos | |
| EA201690039A1 (ru) | Ингибиторы rorc2 и способы их применения | |
| PE20160012A1 (es) | Tratamiento de enfermedades miopaticas y neurogenerativas por agregacion de proteina mediante administracion parenteral | |
| CO2019004004A2 (es) | Composición farmacéutica y método para el tratamiento de la enfermedad del hígado graso no alcohólico | |
| BR112016024020A8 (pt) | composição farmacêutica | |
| EA201692481A1 (ru) | Комбинация, содержащая глюкокортикоид и edo-s101 | |
| CO7131387A2 (es) | Composiciones y métodos de polipéptidos-complejo de quelato de oligonucleótido | |
| CL2012003341A1 (es) | Composicion farmaceutica de administracion oral que compende bendamustina o un ester, una sal o un solvato de la misma, y un excipiente que es un agente tensioactivo no ionico e hidrofilico; combinacion farmaceutica; y su uso para el tratamiento de leucemia linfocitica cronica y el mieloma multiple, entre otras enfermedades. | |
| MX2015012455A (es) | Metodo para el tratamiento de la enfermedad de higado graso. | |
| CO7121334A2 (es) | Formulaciones vesiculares | |
| MX380433B (es) | Combinación de trazodona y gabapentina para el tratamiento de dolor. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant or registration |